FR2016289A1 - Carre's disease combined vaccine - from measles type virus - Google Patents

Carre's disease combined vaccine - from measles type virus

Info

Publication number
FR2016289A1
FR2016289A1 FR6928853A FR6928853A FR2016289A1 FR 2016289 A1 FR2016289 A1 FR 2016289A1 FR 6928853 A FR6928853 A FR 6928853A FR 6928853 A FR6928853 A FR 6928853A FR 2016289 A1 FR2016289 A1 FR 2016289A1
Authority
FR
France
Prior art keywords
virus
pref
measles
carre
attenuated
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
FR6928853A
Other languages
French (fr)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Behringwerke AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG filed Critical Behringwerke AG
Publication of FR2016289A1 publication Critical patent/FR2016289A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/175—Canine distemper virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/0225—Spirochetes, e.g. Treponema, Leptospira, Borrelia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/165—Mumps or measles virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/29—Hepatitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552—Veterinary vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10311—Mastadenovirus, e.g. human or simian adenoviruses
    • C12N2710/10334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18411—Morbillivirus, e.g. Measles virus, canine distemper
    • C12N2760/18434—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Combined vaccines against Carre's disease are prepd. from strains of measles-type virus attenuated by passage in primate tissue culture, by adapting pref. attenuated measles virus by at least 10 passages in tissue culture of organs of the Canidae or Mustelidae family, followed by recovery of the virus and conversion into a vaccine by known methods. The vaccine has a titre of measles-type virus of 103-106 (pref. 104.5-105) TCID50/ml. Prefd. vaccines also contain attenuated Carre's disease virus (pref. 103.5-104.5 TCID50/ml) and/or inactivated canine contagious hepatitis virus (pref. with a complement fixation rate of 1:80+) and/or inactivated leptospires. e.g. Leptospira canicola and icterohaemorrhagiae (pref. 108-109 organisms/ml). These vaccines are particularly useful in protecting young animals.
FR6928853A 1968-08-23 1969-08-22 Carre's disease combined vaccine - from measles type virus Withdrawn FR2016289A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE1792356A DE1792356C2 (en) 1968-08-23 1968-08-23 Distemper combination vaccines and processes for their manufacture

Publications (1)

Publication Number Publication Date
FR2016289A1 true FR2016289A1 (en) 1970-05-08

Family

ID=5707386

Family Applications (1)

Application Number Title Priority Date Filing Date
FR6928853A Withdrawn FR2016289A1 (en) 1968-08-23 1969-08-22 Carre's disease combined vaccine - from measles type virus

Country Status (5)

Country Link
AT (1) AT297219B (en)
BE (1) BE737945A (en)
DE (1) DE1792356C2 (en)
FR (1) FR2016289A1 (en)
NL (1) NL6912389A (en)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000029018A1 (en) * 1998-11-12 2000-05-25 Changchun Institute Of Biological Products Ministry Of Public Health Combined vaccine against both hav and measle virus and method of producing it
CN1062770C (en) 1998-11-12 2001-03-07 卫生部长春生物制品研究所 Vaccine both for hepatitis A and measles and production method therefor

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE634903A (en) *
US3143474A (en) * 1962-07-30 1964-08-04 Sterling Drug Inc Preparation of duck-embryo modified infectious canine hepatitis virus vaccine
US3285817A (en) * 1965-08-17 1966-11-15 Philips Roxane Method of protecting dogs at birth against canine distemper

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT248791B (en) * 1963-03-07 1966-08-10 Philips Electronic Pharma Method of protecting dogs from distemper

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE634903A (en) *
US3143474A (en) * 1962-07-30 1964-08-04 Sterling Drug Inc Preparation of duck-embryo modified infectious canine hepatitis virus vaccine
US3285817A (en) * 1965-08-17 1966-11-15 Philips Roxane Method of protecting dogs at birth against canine distemper

Also Published As

Publication number Publication date
AT297219B (en) 1972-03-10
DE1792356C2 (en) 1983-03-03
BE737945A (en) 1970-02-25
DE1792356A1 (en) 1971-11-18
NL6912389A (en) 1970-02-25

Similar Documents

Publication Publication Date Title
PE20020126A1 (en) VACCINE COMPOSITION
PL304419A1 (en) Urease based vaccine against heliobacter infections
HRP970383A2 (en) Polynucleotide vaccine formula, particularly for treating bovine respiratory disease
OA12915A (en) Vaccine for respiratory and reproductive system infections in cattle.
Turner et al. Human diploid cell strain rabies vaccine: Rapid prophylactic immunisation of volunteers with small doses
RU2005128790A (en) MODIFIED LIVING VACCINES CONTAINING ANTI-VIRVINOUS VIRVES OF TYPE 1 (BHV-1 (IBR)) AND / OR VIRVES OF ANIMAL VIRAL DIARRHEA (BVDV), FOR PREGNANT AND TREATED SKIN
LU91155I2 (en) Combination of diphtheria toxoid, tetanus toxoid, pertussis toxoid, filamentous hemagglutininin, pertactin, pertussis fimbrial agglutinogens 2 and 3 and inactivated poliovirus type 1, type 2 and type 3.
US4110433A (en) Equine rhinopneumonitis virus
US4571386A (en) Feline infectious peritonitis vaccine
de Baugés et al. Effect of antibiotic therapy and strain-19 vaccination on the spread of Brucella melitensis within an infected dairy herd
FR2016289A1 (en) Carre's disease combined vaccine - from measles type virus
US4034081A (en) Vaccines against feline leukemia
US3966907A (en) Vaccines against feline leukemia
GB1071922A (en) Improvements in or relating to vaccines
ES379642A1 (en) Diethylaminoethyl dextran as an adjuvant for vaccines for active immunization
EP0011865B1 (en) Feline infectious peritonitis vaccine and process for its preparation
ES2269672T3 (en) VACCINE AGAINST MYCOPLASMA INACTIVATED BY SAPONINA.
GB1462545A (en) Feline rhinotracheitis vaccine and production thereof
EP0562136A1 (en) Live vaccine to getah virus infectious disease, and trivalent live vaccine to Japanese encephalitis virus, porcine parvovirus and getah virus infectious diseases
Milzer et al. Active immunization of mice with ultraviolet-inactivated lymphocytic choriomeningitis virus vaccine and results of immune serum therapy
Cohen et al. Two injections of diphtheria-tetanus-pertussis-polio vaccine as the backbone of a simplified immunization schedule in developing countries
Cabasso et al. Prospects for measles immunization with reference to the relationship between distemper and measles viruses
Joklik Antigenic relationships between the proteins of the three serotypes of reovirus.
GB1399782A (en) Vaccines for immunization against kennel cough
GB1058340A (en) Transmissible gastroenteritis vaccines and method of producing the same

Legal Events

Date Code Title Description
ST Notification of lapse